Disitamab vedotin targets HER2, not beta-tubulin. After HER2-mediated internalization, the MMAE payload binds the β-tubulin (vinca) site, inhibiting microtubule polymerization and causing G2/M arrest and apoptosis; tubulin expression alone does not determine killing.